Previous 10 | Next 10 |
Eiger BioPharmaceuticals (NASDAQ:EIGR) announces completion of enrollment in the Phase 3 D-LIVR study evaluating two different treatment regimens containing Lonafarnib for the treatment of chronic hepatitis delta virus (HDV) infection. The two regimens include all-oral Lonafarnib boosted...
Eiger BioPharmaceuticals Announces Complete Enrollment of D-LIVR, the Largest Phase 3 Study in Hepatitis Delta Virus (HDV), Investigating Lonafarnib, the Only Oral Agent in Development for HDV - Potential for Approval of Two Lonafarnib-based Regimens - Over 400 Patients Enro...
Eiger BioPharmaceuticals to Host Conference Call for Third Quarter 2021 Financial Results and Business Update on Thursday, November 4 - Live Conference Call and Webcast at 4:30 PM ET - PR Newswire PALO ALTO, Calif. , Oct. 21, 2021 /PRNewswire/ -- Eiger B...
Eiger BioPharmaceuticals Announces Interim Analysis and Continuation of Dosing of Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients - Data Safety Monitoring Board recommends continuation of Peginterferon Lambda - Interim analysis of 453 p...
Eiger BioPharmaceuticals to Participate in Upcoming September 2021 Investor Conferences PR Newswire PALO ALTO, Calif. , Sept. 1, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the develo...
Eiger BioPharmaceuticals, Inc. (EIGR) Q2 2021 Earnings Conference Call August 05, 2021, 04:30 PM ET Company Participants Sri Ryali - Chief Financial Officer David Cory - President and Chief Executive Officer Eldon Mayer - Chief Commercial Officer Ingrid Choong - Senior Vice President, Clinica...
Eiger BioPharmaceuticals (NASDAQ:EIGR): Q2 GAAP EPS of -$0.57 misses by $0.02. Revenue of $2.09M misses by $0.06M. Cash, cash equivalents, and investments as of June 30, 2021, totaled $139.8M compared to $160.5M on March 31, 2021. Press Release For further details see: Eiger BioPharmace...
Eiger BioPharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update - HDV Platform Strategy Rapidly Advancing - Phase 3 HDV D-LIVR (Lonafarnib) >90% Enrolled; On-Track for Full Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) On-Track f...
Score Media and Gaming (NASDAQ:SCR) +65% Penn National Gaming inks deal to acquire Score Media and Gaming Ensysce Biosciences (NASDAQ:ENSC) +38% announces notice of allowance from the U.S. Patent and trademark office for Patent entitled “compositions comprising enzyme-cl...
Eiger BioPharmaceuticals (NASDAQ:EIGR) announces that the U.S. FDA has granted Breakthrough Therapy Designation for avexitide for the treatment of congenital hyperinsulism (HI). Shares up more than 11% premarket. Breakthrough Therapy status is a process designed to expedite the deve...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...